MYC protein expression was unaltered in both YB-1 knockdown cell lines (Louisa Taylor, Ian Kerr & Beth Coyle, University of Nottingham, UK, observation, 2021) indicating that this inhibitory effect occurs at an activity level, a finding with potential therapeutic implications given the association of MYC/MYCN amplification with treatment-refractory disease and relapse in medulloblastoma [34,35]. This evidence concerns the gene MYC and medulloblastoma.